Furthermore, it has been suggested that breast cancer stem cells may selectively express HER2 [59,45]) and that inhibition of this pathway could have beneficial consequences for breast cancer patients with both HER2-positive and HER2-negative disease [47,48]. This evidence concerns the gene ERBB2 and breast cancer.